AI Science Tracker
EN

Shanghai Chest Hospital

1 discovery from 2026

Discoveries

STEAP4-linked immune changes were examined in myocardial-infarction and lung-cancer comorbidity

Source check: Source checked. Not independent scientific confirmation.

Finding: Integrated patient-data analyses associated STEAP4 with immune dysregulation in myocardial-infarction and non-small-cell lung-cancer comorbidity. Follow-up experiments in a mouse comorbidity model and cell assays examined STEAP4 perturbation; the findings are preclinical and do not establish a human treatment.

Technology: Machine-learning-assisted transcriptomic analysis identified STEAP4; experimental perturbation was assessed in cellular and mouse models.

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Machine-learning-assisted transcriptomic analysis identified STEAP4; experimental perturbation was assessed in cellular and mouse models.
Test and result
The study combined transcriptomic analyses with a myocardial-infarction/NSCLC mouse model and cellular assays; STEAP4 perturbation was associated with changes in cardiac function, fibrosis, tumor growth and immune measures.
Limitation / still unknown
Bioinformatic and preclinical evidence; no clinical intervention or human therapeutic benefit established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13364855/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.